A Long-Term, Multi-Center, Open-Label Safety Study with Oral 20 or 40 Mg/d Doses of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients with Motor
|Effective start/end date||8/19/04 → 9/1/08|
- LINEBERY RES ASSOC LLC
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.